NCT04322461

Brief Summary

A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable parkinson-disease

Timeline
Completed

Started May 2022

Typical duration for not_applicable parkinson-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 24, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 26, 2020

Completed
2.1 years until next milestone

Study Start

First participant enrolled

May 1, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 27, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 27, 2024

Completed
Last Updated

June 3, 2025

Status Verified

May 1, 2025

Enrollment Period

2.1 years

First QC Date

March 24, 2020

Last Update Submit

May 28, 2025

Conditions

Parkinson DiseaseAlzheimer Disease

Keywords

AlzheimerParkinsonKetonesmedium chain triglyceridescognitionbrain

Outcome Measures

Primary Outcomes (2)

  • Cognition

    Measure of cognition with CANTAB

    2 months, evaluation before and after intervention

  • Ketones

    Measurement of ketones concentrations

    2 months, evaluation before and after intervention

Secondary Outcomes (1)

  • Endocannabinoids

    2 months, evaluation before and after intervention

Study Arms (2)

Parkinson disease

EXPERIMENTAL

2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.

Dietary Supplement: Betaquik MCT supplement

Alzheimer's disease

EXPERIMENTAL

2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.

Dietary Supplement: Betaquik MCT supplement

Interventions

Betaquik MCT supplementDIETARY_SUPPLEMENT

50g/day divided in 3. Breakfast, lunch and dinner

Alzheimer's diseaseParkinson disease

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Alzheimer's or parkinson disease diagnostic
  • Stable medication associated with the disease
  • Able to consent
  • Presence of an accompanying person for the first and last visit.
  • Ability to read and talk in French

You may not qualify if:

  • MMSE \< 20
  • MCT or coconut oil supplementation
  • Coconut allergy
  • Cannabis, THC or CBD consumption
  • Excessive alcohol consumption
  • Physical activity 3x/week
  • Presence of an metallic object in the body
  • Impossibility to lay in dorsal decubitus for 40 minutes
  • Cardiac disease
  • Any uncontrolled disease that could interfer with the project.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre de recherche sur le vieillissement

Sherbrooke, Quebec, J1H 4C4, Canada

Location

MeSH Terms

Conditions

Parkinson DiseaseAlzheimer DiseaseKetosis

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesDementiaTauopathiesNeurocognitive DisordersMental DisordersAcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Stephen Cunnane, Ph.D.

    Université de Sherbrooke

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2020

First Posted

March 26, 2020

Study Start

May 1, 2022

Primary Completion

May 27, 2024

Study Completion

May 27, 2024

Last Updated

June 3, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations

CA(1)